Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Clinical Significance of Chemokine Receptor CXCR4 and CCR7 mRNA Expression in Patients With Colorectal Cancer

SHINSUKE NAGASAWA, KAZUHITO TSUCHIDA, MANABU SHIOZAWA, YUKIHIKO HIROSHIMA, YAYOI KIMURA, ITARU HASHIMOTO, HAYATO WATANABE, KAZUKI KANO, MASAKATSU NUMATA, TORU AOYAMA, SUMITO SATO, TAKANOBU YAMADA, HIROSHI TAMAGAWA, NAOTO YAMAMOTO, TAKASHI OGATA, SOICHIRO MORINAGA, NORIO YUKAWA, YASUSHI RINO, MUNETAKA MASUDA, HIROSHI SAEKI, YOHEI MIYAGI and TAKASHI OSHIMA
Anticancer Research September 2021, 41 (9) 4489-4495; DOI: https://doi.org/10.21873/anticanres.15259
SHINSUKE NAGASAWA
1Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan;
2Department of Surgery, Yokohama City University, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KAZUHITO TSUCHIDA
1Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan;
2Department of Surgery, Yokohama City University, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MANABU SHIOZAWA
1Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YUKIHIKO HIROSHIMA
3Kanagawa Cancer Center Research Institute, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YAYOI KIMURA
4Advanced Medical Research Center, Yokohama City University, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ITARU HASHIMOTO
1Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HAYATO WATANABE
1Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KAZUKI KANO
1Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASAKATSU NUMATA
2Department of Surgery, Yokohama City University, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TORU AOYAMA
2Department of Surgery, Yokohama City University, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SUMITO SATO
2Department of Surgery, Yokohama City University, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKANOBU YAMADA
1Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROSHI TAMAGAWA
2Department of Surgery, Yokohama City University, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NAOTO YAMAMOTO
1Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKASHI OGATA
1Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SOICHIRO MORINAGA
1Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NORIO YUKAWA
2Department of Surgery, Yokohama City University, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YASUSHI RINO
2Department of Surgery, Yokohama City University, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MUNETAKA MASUDA
2Department of Surgery, Yokohama City University, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROSHI SAEKI
5Department of Gastrointestinal Surgery, Gunma University, Maebashi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOHEI MIYAGI
3Kanagawa Cancer Center Research Institute, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKASHI OSHIMA
1Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: oshimat@kcch.jp
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: The chemokine receptors C-X-C chemokine receptor type 4 (CXCR4) and C-C chemokine receptor type 7 (CCR7) play an important role in the invasion and metastasis of cancer. This study investigated the relationship between relative expression of CXCR4 and CCR7 mRNA, clinicopathological factors, and outcomes in patients with colorectal cancer (CRC). Patients and Methods: We studied 202 patients who underwent surgery for CRC. The expression levels of CXCR4 and CCR7 mRNA in cancerous tissue were measured using quantitative real-time reverse-transcriptase polymerase chain reaction. Results: High CCR7 mRNA expression levels in CRC tissues were positively associated with tumour size and were more frequently associated with cancer of the rectum than of the colon. Moreover, outcomes were significantly poorer in patients with high CCR7 mRNA expression than in those with low expression. On multivariate Cox regression analysis, a higher CCR7 mRNA expression level was a significant independent predictor of poorer overall survival in patients with CRC. Conclusion: Overexpression of CCR7 mRNA may be a useful independent prognostic factor in patients with CRC.

Key Words:
  • CXCR4
  • CCR7
  • colorectal cancer
  • prognostic factors

In 2020, colorectal cancer (CRC) was the third most commonly diagnosed cancer worldwide and accounted for 10% of all cancer, with 1,414,259 new cases reported (1). Moreover, in the same year, CRC was the second leading cause of cancer-related mortality, accounting for 9.4% of all cancer-related deaths, with 935,173 deaths recorded (1).

Most cases of CRC are sporadic and not hereditary. In addition, CRC is due to genetic instability and multiple somatic mutations, and about 80% of CRC cases are diagnosed at an early stage and are curable. Surgery is the first choice of treatment for stage I/II CRC. In patients with stage III CRC, the standard treatment is postoperative chemotherapy after curative resection. Multimodality therapy consisting of surgery, chemotherapy and radiotherapy has prolonged survival in patients with resectable stage IV CRC. However, there is still room for improvement in the outcome of treatment, and personalized treatment using biomarkers may improve the outcomes of CRC.

C-X-C chemokine receptor type 4 (CXCR4) and its ligand, C-X-C motif chemokine 12 (CXCL12), are strongly expressed in a variety of tissues, including the lung, liver, and lymph nodes as well as in various types of cancer, where it attracts lymphocytes to these organs (2, 3). On the other hand, interactions between CCR7 and its ligands, C-C motif chemokine ligand 19 (CCL19) and CCL21, play a central role in lymphocyte trafficking and homing to lymph nodes during immune and inflammatory reactions in various organs as well as in various types of cancer (4-6). Furthermore, it has been reported that these chemokine systems play a role in both lymphatic and distant spread of malignant tumours (7-9). There has been a report demonstrating a correlation of CCR7 expression with lymphatic vessel density and lymph node metastasis in an animal model of CRC (9). However, there are few reports on the association between CXCR4 and CCR7 expression levels in CRC tissue and clinicopathological features or on their potential prognostic value in patients with CRC. In this study, we examined the clinical significance of CXCR4 and CCR7 mRNA expression in CRC tissues in patients with this disease.

Patients and Methods

Patients and samples. The study was approved in advance by the Ethics Committees of Kanagawa Cancer Centre, Yokohama, Japan (approval number: epidemiological study-29) and Yokohama City Medical Centre, Yokohama, Japan (approval number: 18-7A-4). Informed consent was secured from each patient before surgery. A total of 202 patients with CRC and underwent surgery from January 2003 to December 2006 at the Kanagawa Cancer Centre and Yokohama City Medical Centre were selected according to the criteria below. The inclusion criteria were as follows: i) Pathological diagnosis of CRC according to the definitions of the eighth edition of the International Union Against Cancer TNM Classification of Malignant Tumours, (10), and ii) patients undergoing surgery. The exclusion criteria were as follows: i) Death before discharge from hospital, ii) receipt of preoperative treatment, and iii) the presence of multiple cancers within 5 years, iv) refusal to participate in this study. Overall survival (OS) was measured from the day of surgery to death. Each CRC tissue sample was immediately embedded in O.C.T. compound (Sakura Fine Technical Co., Ltd., Tokyo, Japan) and stored at −80°C. All sections sliced from frozen samples were stained with haematoxylin and eosin. Sections that consisted of >80% carcinoma cells were used to extract total RNA.

RNA extraction and complementary DNA (cDNA) synthesis. Total RNA was extracted from CRC tissue samples using TRIzol reagent (Gibco, Life Tech, Gaithersburg, MD, USA). Complementary DNA (cDNA) was synthesised using an iScript cDNA Synthesis kit (Bio-Rad Laboratories, Hercules, CA, USA) from 200 ng of total RNA. The cDNA was diluted 20% with distilled water and stored at –20°C.

Quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR). qRT-PCR was carried out using iQ SYBR Green Supermix (Bio-Rad Laboratories). PCR was carried out in a total volume of 15 μl consisting of cDNA made from 0.75 mg of RNA, 270 nM of each primer, 7.5 μl of iQ SYBR Green Supermix containing 0.4 mM each of dCTP, dTTP, dATP and dGTP, and 50 U/ml of iTag DNA polymerase. The PCR conditions was performed 3 min at 95°C, followed by 35 cycles of denaturation of the cDNA for 15 s at 95°C, annealing for 15 s at an appropriate temperature (Table I), and a primer extension for 30 s at 72°C, followed by 72°C for 10 min. The primer sequences of CXCR4, CCR7, and b-actin, which was used as an internal control, are shown in Table I.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Polymerase chain reaction primers and conditions.

Statistical analysis. The expression levels of CXCR4 and CCR7 mRNA were categorised as low (n=101) or high (n=101) according to the median expression of CXCR4 and CCR7 mRNA in CRC tissue. The relationship between CXCR4 and CCR7 mRNA expression and clinicopathological factors was examined using the chi-squared test. The OS curve was made using the Kaplan-Meier method, and differences in OS were examined using the log-rank test. Univariate and multivariate analyses for predictive factors of OS were carried out using a Cox proportional hazards regression model. All statistical analyses were carried out using IBM SPSS Statistics version 20 (IBM Corp., Armonk, NY, USA). Two-tailed p-values were calculated. Differences were considered statistically significant when the p-value was less than 0.05.

Results

Relationship between mRNA expression levels of CXCR4 and CCR7 and clinicopathological factors. There was no significant association between CXCR4 mRNA expression and any clinicopathological factor. High CCR7 mRNA expression levels in CRC tissues were positively associated with tumour size and with cancer of the rectum than of the colon (Table II).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Relationship between C-X-C chemokine receptor type 4 (CXCR4) and C-C chemokine receptor type 7 (CCR7) mRNA expression levels and clinicopathological features.

Relationship between CXCR4 and CCR7 mRNA expression levels in CRC tissues and patient outcomes. There was no significant difference in OS according to the CXCR4 expression level in CRC tissue (Figure 1A). In contrast, the 5-year OS rate was significantly poorer in patients with high CCR7 mRNA expression in CRC tissue than in those with low CCR7 mRNA expression (p=0.0014, log-rank test; Figure 1B). The median follow-up period was 61.6 months.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Comparison of overall survival after surgery according to C-X-C chemokine receptor type 4 (CXCR4) and C-C chemokine receptor type 7 (CCR7) mRNA expression levels in patients with colorectal cancer. A: Overall survival did not differ significantly according to the CXCR4 expression level. B: The overall survival rate was significantly lower in patients with high CCR7 gene expression than in those with low CCR7 gene expression (p=0.0013, log-rank test).

Univariate and multivariate analyses for OS of clinicopathological factors and CCR7 mRNA expression levels. On univariate Cox regression analysis, tumour diameter, histological type, depth of invasion, lymph node metastasis, lymphatic invasion, distant metastasis, pStage, and high expression level of CCR7 mRNA were selected as significant predictors of OS (Table III). On multivariate Cox regression analysis, high expression of CCR7 mRNA was identified as a significant independent predictor of poorer OS (p=0.037; Table III).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table III.

Univariate and multivariate analyses to identify clinicopathological factors affecting overall survival.

Discussion

In this study, we examined whether CXCR4 and CCR7 mRNA expression in CRC tissue was associated with clinicopathological factors and outcomes in patients with CRC. High CCR7 mRNA expression levels in CRC tissues were positively associated with tumour size and with rectal rather than colonic cancer. In addition, the 5-year OS rate was significantly poorer in patients with high CCR7 mRNA expression than in those with low CCR7 mRNA expression. Furthermore, multivariate analysis demonstrated that overexpression of CCR7 mRNA was an independent predictive factor of outcomes in patients with CRC.

Several chemokines and their receptors have been found to play important roles in tumour progression (7). Furthermore, interactions between CXCR4 and its ligand CXCL12 may direct several key processes in the directional regulation of haematopoiesis and migration of metastatic tumour cells (11). CCR7, stimulated by its ligand CCL21, may induce invasion and migration of overexpression of CCR7 cancer cells into lymph nodes in a manner similar to that found for lymphocyte homing (4-6). Therefore, the chemokine receptors CXCR4 and CCR7 are suggested to play an important role in lymphatic invasion and tumour progression in cancer. We examined whether CXCR4 and CCR7 mRNA expression levels were associated with clinicopathological features and outcomes in patients with CRC.

Firstly, we examined the relationship between CXCR4 and CCR7 mRNA expression levels in CRC tissues and clinicopathological features. The effects of CXCR4 and its ligands on lymphatic spread and of CCR7 on distant metastasis have been demonstrated in various types of cancer (9, 12-23). As for associations between their expression levels, it was reported that CXCR4 expression levels were positively correlated with TNM stage, lymph node metastasis, and distant metastasis in 68 patients with CRC (24). A further study demonstrated that strong expression of CXCR4 was significantly associated with advanced tumour stage (Union for International Cancer Control), lymph node metastasis, and distant metastasis in 92 patients with CRC (24). It was reported that high expression of the chemokine receptor CCR7 at the tumour invasive front was an independent and powerful predictor of regional lymph node metastases in 94 patients with CRC without distant metastasis. In addition, overexpression of CCR7 correlated positively only with location of the primary tumour in the rectum and not with any other clinicopathological features (22). In our present study, there was no relationship between CXCR4 gene expression levels and clinicopathological features. In contrast, a high CCR7 mRNA expression level was related to greater tumour size and location in the rectum.

We then examined the relationship between CXCR4 and CCR7 mRNA expression levels in CRC tissue and outcomes in patients with CRC. High expression of both CXCR4 and CCR7 correlated with poor outcomes in various types of cancer (11-14, 22-25). However, a clear association between CXCR4 or CCR7 mRNA expression in CRC tissue and outcomes has yet to be established in patients with CRC. It was reported that high CXCR4 mRNA expression in primary CRC was significantly associated with recurrence, poorer survival, and liver metastasis (30, 31). Another study demonstrated thatin immunohistochemical experiments, CCR7 expression at the tumour invasion front was a significant prognostic factor, whereas CXCR4 expression was not observed (32). Furthermore, another study found no significant relationship between CXCR4 and CCR7 expression levels and patient survival (25). In our study, CXCR4 mRNA expression was unrelated to survival in patients with CRC; however, high CCR7 mRNA expression in cancerous tissue was significantly associated with poorer OS. Moreover, on multivariate analyses, high expression of CCR7 mRNA in CRC tissue was a significant independent predictor of poorer OS in patients with CRC.

The mechanism of the association between CCR7 mRNA overexpression in CRC tissue and poor patient survival remains unclear. Several previous studies reported that CCR7 has important roles in tumor formation, invasion, migration, and metastasis (33-36). In addition to chemotaxis by chemokines, mechanisms for the enhancement of tumorigenesis and cell survival by chemokines have been described. One study demonstrated that activation of CCR7 through ligands present in the tumour microenvironment contributed directly to tumour formation via immunologically mediated mechanisms (33). Furthermore, CCR7 was shown to activate phosphoinositide-3 kinase to promote tumour invasion (34). Another report suggested that CCR7 promotes expression of c2H2-zinc finger type transcription factor SNAI1 and induces epithelial–mesenchymal transition with, as a result, cell cycle progression, proliferation, invasion, and metastasis of gastric cancer (35). CCR7 was reported to increase invasion and migration of cancer cells, and lymph node metastasis by facilitating expression of vascular endothelial growth factors, thereby facilitating the Wnt and phosphorylated extracellular signal-regulated kinase pathways (36). While only a hypothesis, it is possible that the above mechanism of tumour formation, invasion, migration, and lymph node metastasis involving CCR7 is associated with poor survival after surgery in patients with CRC and overexpression of CCR7 mRNA.

This study has several limitations. Firstly, we only examined the expression of CXCR4 and CCR7 mRNA in CRC tissues of patients with CRC. We believe that the association between CCR7 and CXCR4 protein expression and CXCR4 and CCR7 mRNA expression should be analysed by immunohistochemical studies using the same specimens. Secondly, heterogeneity in the CRC specimens was an important problem. The specimens used for mRNA extraction were about 5-mm square CRC tissue specimens; although these specimens were collected from the central part of the entire tumour, they did not faithfully represent the entire tumour.

In conclusion, overexpression of CCR7 mRNA in cancerous tissue may be a useful independent prognostic marker in patients with CRC.

Acknowledgements

The Authors thank all of the patients, their families, and the site staff for their participation in this study.

Footnotes

  • ↵* These Authors contributed equally to this study.

  • Authors’ Contributions

    KT, SN, MS and TO designed the study. Data collection and literature searches were performed by HW, KK, MN, SS, TY HT, NY, NY, TO, SM, and RY. Data analysis was performed by KT, SN, IH, TA, YH, YK, MM, HS, YM, and TO. Data interpretation was performed by all investigators. The article and figures were drafted by KT, SN, and TO. Finally, the article was revised and approved by all investigators. Thus, all of the Authors actively participated in this study.

  • Conflicts of Interest

    The Authors declare that there are no conflicts of interest regarding this study.

  • Received June 6, 2021.
  • Revision received July 3, 2021.
  • Accepted July 6, 2021.
  • Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

References

  1. ↵
    1. International Agency for Research on Cancer
    : Global Cancer observatory. Available at: https://gco.iarc.fr/today/data/factsheets/cancers/10_8_9-Colorectum-fact-sheet.pdf [Last accessed on 11th May, 2021]
  2. ↵
    1. Phillips RJ,
    2. Burdick MD,
    3. Lutz M,
    4. Belperio JA,
    5. Keane MP and
    6. Strieter RM
    : The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med 167(12): 1676-1686, 2003. PMID: 12626353. DOI: 10.1164/rccm.200301-071OC
    OpenUrlCrossRefPubMed
  3. ↵
    1. Murdoch C
    : CXCR4: chemokine receptor extraordinaire. Immunol Rev 177: 175-184, 2000. PMID: 11138774. DOI: 10.1034/j.1600-065x.2000.17715.x
    OpenUrlCrossRefPubMed
  4. ↵
    1. Hirao M,
    2. Onai N,
    3. Hiroishi K,
    4. Watkins SC,
    5. Matsushima K,
    6. Robbins PD,
    7. Lotze MT and
    8. Tahara H
    : CC chemokine receptor-7 on dendritic cells is induced after interaction with apoptotic tumor cells: critical role in migration from the tumor site to draining lymph nodes. Cancer Res 60(8): 2209-2217, 2000. PMID: 10786686.
    OpenUrlAbstract/FREE Full Text
    1. Oliveira-Neto HH,
    2. de Souza PP,
    3. da Silva MR,
    4. Mendonça EF,
    5. Silva TA and
    6. Batista AC
    : The expression of chemokines CCL19, CCL21 and their receptor CCR7 in oral squamous cell carcinoma and its relevance to cervical lymph node metastasis. Tumour Biol 34(1): 65-70, 2013. PMID: 22976543. DOI: 10.1007/s13277-012-0511-3
    OpenUrlCrossRefPubMed
  5. ↵
    1. Vahedi L,
    2. Ghasemi M,
    3. Yazdani J,
    4. Ranjbar S,
    5. Nouri B,
    6. Alizadeh A and
    7. Afshar P
    : Investigation of CCR7 marker expression using immunohistochemical method and its association with clinicopathologic properties in patients with breast cancer. Int J Hematol Oncol Stem Cell Res 12(2): 103-110, 2018. PMID: 30233771.
    OpenUrlPubMed
  6. ↵
    1. Raman D,
    2. Baugher PJ,
    3. Thu YM and
    4. Richmond A
    : Role of chemokines in tumor growth. Cancer Lett 256(2): 137-165, 2007. PMID: 17629396. DOI: 10.1016/j.canlet.2007.05.013
    OpenUrlCrossRefPubMed
    1. Ji RC
    : Lymph nodes and cancer metastasis: New perspectives on the role of intranodal lymphatic sinuses. Int J Mol Sci 18(1): 51, 2016. PMID: 28036019. DOI: 10.3390/ijms18010051
    OpenUrlCrossRefPubMed
  7. ↵
    1. Müller A,
    2. Homey B,
    3. Soto H,
    4. Ge N,
    5. Catron D,
    6. Buchanan ME,
    7. McClanahan T,
    8. Murphy E,
    9. Yuan W,
    10. Wagner SN,
    11. Barrera JL,
    12. Mohar A,
    13. Verástegui E and
    14. Zlotnik A
    : Involvement of chemokine receptors in breast cancer metastasis. Nature 410(6824): 50-56, 2001. PMID: 11242036. DOI: 10.1038/35065016
    OpenUrlCrossRefPubMed
  8. ↵
    1. Brierley JD,
    2. Gospodarowicz MK and
    3. Wittekind C
    : TNM Classification of Malignant Tumors. Eighth Edition. West Sussex: Wiley-Blackwell, 2017.
  9. ↵
    1. Feng LY,
    2. Ou ZL,
    3. Wu FY,
    4. Shen ZZ and
    5. Shao ZM
    : Involvement of a novel chemokine decoy receptor CCX-CKR in breast cancer growth, metastasis and patient survival. Clin Cancer Res 15(9): 2962-2970, 2009. PMID: 19383822. DOI: 10.1158/1078-0432.CCR-08-2495
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Yu S,
    2. Duan J,
    3. Zhou Z,
    4. Pang Q,
    5. Wuyang J,
    6. Liu T,
    7. He X,
    8. Xinfa L and
    9. Chen Y
    : A critical role of CCR7 in invasiveness and metastasis of SW620 colon cancer cell in vitro and in vivo. Cancer Biol Ther 7(7): 1037-1043, 2008. PMID: 18437055. DOI: 10.4161/cbt.7.7.6065
    OpenUrlCrossRefPubMed
    1. Burger JA and
    2. Kipps TJ
    : CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 107(5): 1761-1767, 2006. PMID: 16269611. DOI: 10.1182/blood-2005-08-3182
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Wang D,
    2. Wang X,
    3. Si M,
    4. Yang J,
    5. Sun S,
    6. Wu H,
    7. Cui S,
    8. Qu X and
    9. Yu X
    : Exosome-encapsulated miRNAs contribute to CXCL12/CXCR4-induced liver metastasis of colorectal cancer by enhancing M2 polarization of macrophages. Cancer Lett 474: 36-52, 2020. PMID: 31931030. DOI: 10.1016/j.canlet.2020.01.005
    OpenUrlCrossRefPubMed
    1. Kodama J,
    2. Hasengaowa, Kusumoto T,
    3. Seki N,
    4. Matsuo T,
    5. Ojima Y,
    6. Nakamura K,
    7. Hongo A and
    8. Hiramatsu Y
    : Association of CXCR4 and CCR7 chemokine receptor expression and lymph node metastasis in human cervical cancer. Ann Oncol 18(1): 70-76, 2007. PMID: 17032700. DOI: 10.1093/annonc/mdl342
    OpenUrlCrossRefPubMed
    1. Tsuzuki H,
    2. Takahashi N,
    3. Kojima A,
    4. Narita N,
    5. Sunaga H,
    6. Takabayashi T and
    7. Fujieda S
    : Oral and oropharyngeal squamous cell carcinomas expressing CCR7 have poor prognoses. Auris Nasus Larynx 33(1): 37-42, 2006. PMID: 16223574. DOI: 10.1016/j.anl.2005.07.019
    OpenUrlCrossRefPubMed
    1. Ding Y,
    2. Shimada Y,
    3. Maeda M,
    4. Kawabe A,
    5. Kaganoi J,
    6. Komoto I,
    7. Hashimoto Y,
    8. Miyake M,
    9. Hashida H and
    10. Imamura M
    : Association of CC chemokine receptor 7 with lymph node metastasis of esophageal squamous cell carcinoma. Clin Cancer Res 9(9): 3406-3412, 2003. PMID: 12960129.
    OpenUrlAbstract/FREE Full Text
    1. Mashino K,
    2. Sadanaga N,
    3. Yamaguchi H,
    4. Tanaka F,
    5. Ohta M,
    6. Shibuta K,
    7. Inoue H and
    8. Mori M
    : Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma. Cancer Res 62(10): 2937-2941, 2002. PMID: 12019175.
    OpenUrlAbstract/FREE Full Text
    1. Takanami I
    : Overexpression of CCR7 mRNA in nonsmall cell lung cancer: correlation with lymph node metastasis. Int J Cancer 105(2): 186-189, 2003. PMID: 12673677. DOI: 10.1002/ijc.11063
    OpenUrlCrossRefPubMed
    1. Geminder H,
    2. Sagi-Assif O,
    3. Goldberg L,
    4. Meshel T,
    5. Rechavi G,
    6. Witz IP and
    7. Ben-Baruch A
    : A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma. J Immunol 167(8): 4747-4757, 2001. PMID: 11591806. DOI: 10.4049/jimmunol.167.8.4747
    OpenUrlAbstract/FREE Full Text
    1. Taichman RS,
    2. Cooper C,
    3. Keller ET,
    4. Pienta KJ,
    5. Taichman NS and
    6. McCauley LK
    : Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 62(6): 1832-1837, 2002. PMID: 11912162.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Cabioglu N,
    2. Yazici MS,
    3. Arun B,
    4. Broglio KR,
    5. Hortobagyi GN,
    6. Price JE and
    7. Sahin A
    : CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer. Clin Cancer Res 11(16): 5686-5693, 2005. PMID: 16115904. DOI: 10.1158/1078-0432.CCR-05-0014
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Günther K,
    2. Leier J,
    3. Henning G,
    4. Dimmler A,
    5. Weissbach R,
    6. Hohenberger W and
    7. Förster R
    : Prediction of lymph node metastasis in colorectal carcinoma by expressionof chemokine receptor CCR7. Int J Cancer 116(5): 726-733, 2005. PMID: 15828050. DOI: 10.1002/ijc.21123
    OpenUrlCrossRefPubMed
  14. ↵
    1. Wu Y,
    2. Jin M,
    3. Xu H,
    4. Shimin Z,
    5. He S,
    6. Wang L and
    7. Zhang Y
    : Clinicopathologic significance of HIF-1α, CXCR4, and VEGF expression in colon cancer. Clin Dev Immunol 2010: 537531, 2010. PMID: 20953377. DOI: 10.1155/2010/537531
    OpenUrlCrossRefPubMed
  15. ↵
    1. Schimanski CC,
    2. Schwald S,
    3. Simiantonaki N,
    4. Jayasinghe C,
    5. Gönner U,
    6. Wilsberg V,
    7. Junginger T,
    8. Berger MR,
    9. Galle PR and
    10. Moehler M
    : Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clin Cancer Res 11(5): 1743-1750, 2005. PMID: 15755995. DOI: 10.1158/1078-0432.CCR-04-1195
    OpenUrlAbstract/FREE Full Text
    1. Yan C,
    2. Zhu ZG,
    3. Yu YY,
    4. Ji J,
    5. Zhang Y,
    6. Ji YB,
    7. Yan M,
    8. Chen J,
    9. Liu BY,
    10. Yin HR and
    11. Lin YZ
    : Expression of vascular endothelial growth factor C and chemokine receptor CCR7 in gastric carcinoma and their values in predicting lymph node metastasis. World J Gastroenterol 10(6): 783-790, 2004. PMID: 15040017. DOI: 10.3748/wjg.v10.i6.783
    OpenUrlCrossRefPubMed
    1. Liu Y,
    2. Ji R,
    3. Li J,
    4. Gu Q,
    5. Zhao X,
    6. Sun T,
    7. Wang J,
    8. Li J,
    9. Du Q and
    10. Sun B
    : Correlation effect of EGFR and CXCR4 and CCR7 chemokine receptors in predicting breast cancer metastasis and prognosis. J Exp Clin Cancer Res 29: 16, 2010. PMID: 20181250. DOI: 10.1186/1756-9966-29-16
    OpenUrlCrossRefPubMed
    1. Laverdiere C,
    2. Hoang BH,
    3. Yang R,
    4. Sowers R,
    5. Qin J,
    6. Meyers PA,
    7. Huvos AG,
    8. Healey JH and
    9. Gorlick R
    : Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin Cancer Res 11(7): 2561-2567, 2005. PMID: 15814634. DOI: 10.1158/1078-0432.CCR-04-1089
    OpenUrlAbstract/FREE Full Text
    1. Kaifi JT,
    2. Yekebas EF,
    3. Schurr P,
    4. Obonyo D,
    5. Wachowiak R,
    6. Busch P,
    7. Heinecke A,
    8. Pantel K and
    9. Izbicki JR
    : Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer. J Natl Cancer Inst 97(24): 1840-1847, 2005. PMID: 16368946. DOI: 10.1093/jnci/dji431
    OpenUrlCrossRefPubMed
  16. ↵
    1. Wang N,
    2. Wu QL,
    3. Fang Y,
    4. Mai HQ,
    5. Zeng MS,
    6. Shen GP,
    7. Hou JH and
    8. Zeng YX
    : Expression of chemokine receptor CXCR4 in nasopharyngeal carcinoma: pattern of expression and correlation with clinical outcome. J Transl Med 3: 26, 2005. PMID: 15978137. DOI: 10.1186/1479-5876-3-26
    OpenUrlCrossRefPubMed
  17. ↵
    1. Yopp AC,
    2. Shia J,
    3. Butte JM,
    4. Allen PJ,
    5. Fong Y,
    6. Jarnagin WR,
    7. DeMatteo RP and
    8. D’Angelica MI
    : CXCR4 expression predicts patient outcome and recurrence patterns after hepatic resection for colorectal liver metastases. Ann Surg Oncol 19 Suppl 3: S339-S346, 2012. PMID: 21584832. DOI: 10.1245/s10434-011-1774-4
    OpenUrlCrossRefPubMed
  18. ↵
    1. Kim J,
    2. Takeuchi H,
    3. Lam ST,
    4. Turner RR,
    5. Wang HJ,
    6. Kuo C,
    7. Foshag L,
    8. Bilchik AJ and
    9. Hoon DS
    : Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol 23(12): 2744-2753, 2005. PMID: 15837989. DOI: 10.1200/JCO.2005.07.078
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Fang L,
    2. Lee VC,
    3. Cha E,
    4. Zhang H and
    5. Hwang ST
    : CCR7 regulates B16 murine melanoma cell tumorigenesis in skin. J Leukoc Biol 84(4): 965-972, 2008. PMID: 18519742. DOI: 10.1189/jlb.1107776
    OpenUrlCrossRefPubMed
  20. ↵
    1. Liu FY,
    2. Zhao ZJ,
    3. Li P,
    4. Ding X,
    5. Zong ZH and
    6. Sun CF
    : Mammalian target of rapamycin (mTOR) is involved in the survival of cells mediated by chemokine receptor 7 through PI3K/Akt in metastatic squamous cell carcinoma of the head and neck. Br J Oral Maxillofac Surg 48(4): 291-296, 2010. PMID: 19615795. DOI: 10.1016/j.bjoms.2009.06.007
    OpenUrlCrossRefPubMed
  21. ↵
    1. Zhang J,
    2. Zhou Y and
    3. Yang Y
    : CCR7 pathway induces epithelial-mesenchymal transition through up-regulation of Snail signaling in gastric cancer. Med Oncol 32(2): 467, 2015. PMID: 25572817. DOI: 10.1007/s12032-014-0467-9
    OpenUrlCrossRefPubMed
  22. ↵
    1. Yu J,
    2. Tao S,
    3. Hu P,
    4. Wang R,
    5. Fang C,
    6. Xu Y,
    7. Qi D,
    8. Wei Z,
    9. Zhang J and
    10. Tan Q
    : CCR7 promote lymph node metastasis via regulating VEGF-C/D-R3 pathway in lung adenocarcinoma. J Cancer 8(11): 2060-2068, 2017. PMID: 28819407. DOI: 10.7150/jca.19069
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Anticancer Research: 41 (9)
Anticancer Research
Vol. 41, Issue 9
September 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Clinical Significance of Chemokine Receptor CXCR4 and CCR7 mRNA Expression in Patients With Colorectal Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Clinical Significance of Chemokine Receptor CXCR4 and CCR7 mRNA Expression in Patients With Colorectal Cancer
SHINSUKE NAGASAWA, KAZUHITO TSUCHIDA, MANABU SHIOZAWA, YUKIHIKO HIROSHIMA, YAYOI KIMURA, ITARU HASHIMOTO, HAYATO WATANABE, KAZUKI KANO, MASAKATSU NUMATA, TORU AOYAMA, SUMITO SATO, TAKANOBU YAMADA, HIROSHI TAMAGAWA, NAOTO YAMAMOTO, TAKASHI OGATA, SOICHIRO MORINAGA, NORIO YUKAWA, YASUSHI RINO, MUNETAKA MASUDA, HIROSHI SAEKI, YOHEI MIYAGI, TAKASHI OSHIMA
Anticancer Research Sep 2021, 41 (9) 4489-4495; DOI: 10.21873/anticanres.15259

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Clinical Significance of Chemokine Receptor CXCR4 and CCR7 mRNA Expression in Patients With Colorectal Cancer
SHINSUKE NAGASAWA, KAZUHITO TSUCHIDA, MANABU SHIOZAWA, YUKIHIKO HIROSHIMA, YAYOI KIMURA, ITARU HASHIMOTO, HAYATO WATANABE, KAZUKI KANO, MASAKATSU NUMATA, TORU AOYAMA, SUMITO SATO, TAKANOBU YAMADA, HIROSHI TAMAGAWA, NAOTO YAMAMOTO, TAKASHI OGATA, SOICHIRO MORINAGA, NORIO YUKAWA, YASUSHI RINO, MUNETAKA MASUDA, HIROSHI SAEKI, YOHEI MIYAGI, TAKASHI OSHIMA
Anticancer Research Sep 2021, 41 (9) 4489-4495; DOI: 10.21873/anticanres.15259
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Assessment of Breakthrough Cancer Pain Among Female Patients With Cancer: Knowledge, Management and Characterization in the IOPS-MS Study
  • Low-dose Apalutamide in Non-metastatic Castration-resistant Prostate Cancer: A Case Series
  • Bone Toxicity Case Report Combining Encorafenib, Cetuximab and WNT974 in a Phase I Trial
Show more Clinical Studies

Similar Articles

Keywords

  • CXCR4
  • CCR7
  • colorectal cancer
  • prognostic factors
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire